US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Lidocaine HCl in all strengths

Reason Lack of sterility assurance.

Pharmedium Services, LLC D-0438-2018
Class II · Moderate risk Terminated

Famciclovir Tablets

Reason Temperature Abuse: Complaints of tablets being wet and stuck together with tablet coating peeled and disintegrated as a result of prolonged exposure to high temp during distribution.

Hetero Labs Limited Unit V NDC 31722-708-30 D-0415-2018
Class II · Moderate risk Terminated

DELFLEX Peritoneal Dialysis Solution

Reason Lack of Assurance of Sterility: Leakage of the peritoneal dialysis (PD) solution bag.

Fresenius Medical Care Renal Therapies Group, LLC NDC 49230-209-30 D-0604-2018
Class II · Moderate risk Terminated

Dry to Normal Skin Starter Kit

Reason Failed Stability Specifications:stability failure at 12 months, long term RT conditions.

Odan Laboratories Ltd D-0232-2018
Class II · Moderate risk Terminated

Day Cream SPF15 Cr¿me de jour FPS 15

Reason Failed Stability Specifications:stability failure at 12 months, long term RT conditions.

Odan Laboratories Ltd D-0231-2018
Class II · Moderate risk Terminated

Divalproex Sodium Delayed Release Tablets USP

Reason Cross Contamination With Other Products: metronidazole powder was found in one bottle of Divalproex Sodium.

Unichem Pharmaceuticals Usa Inc NDC 29300-140-01 D-0228-2018
Class II · Moderate risk Terminated

Fosphenytoin Sodium Injection

Reason Presence of particulate matter

Amneal Pharmaceuticals NDC 70121-1390-1 D-0610-2018
Class II · Moderate risk Terminated

0.25% Acetic Acid Irrigation USP

Reason Presence of Particulate Matter: identified as polyethylene, which is consistent with the material used to manufacture the contain cap

B. Braun Medical Inc NDC 0264-2304-10 D-0112-2018
Class II · Moderate risk Terminated

SPIRIVA HandiHaler

Reason Failed Stability Specifications

Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0075-47 D-0242-2018
Class II · Moderate risk Terminated

Moexipril Hydrochloride and Hydrocholorothiazide Tablets USP

Reason Failed Impurities/Degradation Specifications: High out of specification test result for the Moexipril Diketopiperazine impurity was obtained during routine stability testing.

Teva Pharmaceuticals USA NDC 0093-5213-01 D-0208-2018